public.fnol.cz - /PS/Komise/Eticka/nové studie CTIS 2024/čj. 27 - SÚKL č. 620 -KH schválena s podmínkou/Part II/

[To Parent Directory]

 3/15/2024 10:12 AM      1014265 K1_Vedolizumab-3041_Recruitment and Informed consent procedure_CZE_NotPublic.PDF
 3/15/2024 10:12 AM       401636 L1_Vedolizumab-3041_ICF_Assent_12_14_CZE_Czech_Public.PDF
 3/15/2024 10:12 AM       529413 L1_Vedolizumab-3041_ICF_Assent_15_17_CZE_Czech_Public.PDF
 3/15/2024 10:12 AM       315137 L1_Vedolizumab-3041_ICF_GDPR_Adult_CZE_Czech_Public.PDF
 3/15/2024 10:12 AM       386393 L1_Vedolizumab-3041_ICF_GDPR_Parental_CZE_Czech_Public.PDF
 3/15/2024 10:12 AM       861310 L1_Vedolizumab-3041_ICF_Main_Adult_CZE_Czech_Public.PDF
 3/15/2024 10:12 AM       325564 L1_Vedolizumab-3041_ICF_Main_Parental_CZE_Czech_Public.PDF
 3/15/2024 10:12 AM       173032 L1_Vedolizumab-3041_ICF_Optional_FutureResearch_Adult_CZE_Czech_Public.PDF
 3/15/2024 10:12 AM       179066 L1_Vedolizumab-3041_ICF_Optional_FutureResearch_Parental_CZE_Czech_Public.PDF
 3/15/2024 10:12 AM       143117 L1_Vedolizumab-3041_ICF_PP_CZE_Czech_Public.PDF
 3/15/2024 10:12 AM      3272338 L2_Vedolizumab-3041_Application_Screen_eDiary_Public.PDF
 3/15/2024 10:12 AM       675636 L2_Vedolizumab-3041_Appointment_Card_CZE_Czech_Public.PDF
 3/15/2024 10:12 AM      3245869 L2_Vedolizumab-3041_Brochure_CZE_Czech_Public.PDF
 3/15/2024 10:12 AM       666809 L2_Vedolizumab-3041_Parent Letter_CZE_Czech_Public.PDF
 3/15/2024 10:12 AM       343072 L2_Vedolizumab-3041_Patient_Card_CZE_Czech_Public.PDF
 3/15/2024 10:12 AM       652960 L2_Vedolizumab-3041_QRG_CZE_Czech_Public.PDF
 3/15/2024 10:13 AM      1216419 L2_Vedolizumab-3041_Thank_You_Card_CZE_Czech_Public.PDF
 3/15/2024 10:13 AM       526486 L2_Vedolizumab-3041_Video_CZE_Czech_Public.PDF
 3/15/2024 10:13 AM      3559856 L2_Vedolizumab-3041_Visit Guide-Passport_CZE_Czech_Public.PDF
 3/15/2024 10:13 AM      2541506 L2_Vedolizumab-3041_Visit Guide_CZE_Czech_Public.PDF
 3/15/2024 10:13 AM      3850615 L2_Vedolizumab-3041_Visit_Passport_CZE_Czech_Public.PDF
 3/15/2024 10:13 AM      1086741 M1_CV_PI_Mitrova_Katarina_FN Motol_CZE_NotPublic.PDF
 3/15/2024 10:13 AM      1583612 M2_Vedolizumab-3041_Declaration_of_Interest_Mitrova_Katarina_PI_FN Motol_CZE_NotPublic.PDF
 3/15/2024 10:13 AM       734463 N1_Vedolizumab-3041_Statement_of_Suitability_CZE_Mitrova_Katarina_NotPublic.PDF
 3/15/2024 10:13 AM       823415 N2_Vedolizumab-3041_List_of_participating sites_CZE_NotPublic.PDF
 3/15/2024 10:14 AM       317373 O2_Vedolizumab-3041_Insurance_Terms and Conditions_CZE_Czech_NotPublic.PDF
 3/15/2024 10:14 AM      1409513 P1_Vedolizumab-3041_Compensation_for_Trial_Participants_CZE.PDF
 3/15/2024 10:14 AM       739960 R1_Vedolizumab-3041_Data_Protection_Declaration_CZE_NotPublic.PDF
 3/15/2024 10:14 AM       812562 S1_Vedolizumab-3041_Use_of_Biological_Samples_Declaration_CZE_NotPublic.PDF